Heparan sulphate as a regulator of leukocyte recruitment in inflammation

Current Protein and Peptide Science

Volumn 16, Issue 1, 2015, Pages 77-86

  Kumar, Archana V ^a   Katakam, Sampath K ^a   Urbanowitz, Ann Kathrin ^a   Götte, Martin ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Chemokine; Diapedesis; Heparan sulphate; Heparanase; Intraluminal crawling; Proteoglycan; Selectin; Syndecan

Indexed keywords

ANTITHROMBIN III; CATHEPSIN; CD11B ANTIGEN; CD18 ANTIGEN; CD31 ANTIGEN; CD99 ANTIGEN; CHEMOKINE; DEFENSIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBROBLAST GROWTH FACTOR 2; FOCAL ADHESION KINASE; HEPARAN SULFATE; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 2; JUNCTIONAL ADHESION MOLECULE; L SELECTIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; N ACETYLGLUCOSAMINE; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN; PHOSPHOLIPASE C; PROTEIN CDC42; REACTIVE OXYGEN METABOLITE; SYNDECAN; SYNDECAN 4; TOLL LIKE RECEPTOR; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

ARTICLE; CELL ACTIVATION; DIAPEDESIS; DOWN REGULATION; EXTRACELLULAR MATRIX; GENE SILENCING; HUMAN; INFLAMMATION; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; MACROPHAGE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OLIGOMERIZATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCYTOSIS; UPREGULATION; ANIMAL; CELL ADHESION; IMMUNOLOGY; LEUKOCYTE; LEUKOCYTE ROLLING; METABOLISM; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION;

ANIMALS; CELL ADHESION; CHEMOTAXIS, LEUKOCYTE; HEPARITIN SULFATE; HUMANS; INFLAMMATION; LEUKOCYTE ROLLING; LEUKOCYTES; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION;

EID: 84936768574     PISSN: 13892037     EISSN: 18755550     Source Type: Journal    
DOI: 10.2174/1573402111666150213165054     Document Type: Article

References (122)

1. Götte, M. Syndecans in inflammation. FASEB J., 2003, 17, 575-591.
2. Ley, K., Laudanna, C., Cybulsky, M.I., Nourshargh, S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol., 2007, 7, 678-689.
3. Kolaczkowska, E., Kubes, P. Neutrophil recruitment and function in health and inflammation. Nat. Rev. Immunol., 2013, 13, 159-175.
4. Schmidt, S., Moser, M., Sperandio, M. The molecular basis of leukocyte recruitment and its deficiencies. Mol. Immunol., 2013, 55, 49-58.
5. Amulic, B., Cazalet, C., Hayes, G.L., Metzler, K.D., Zychlinsky, A. Neutrophil function: from mechanisms to disease. Annu. Rev. Immunol., 2012, 30, 459-489.
6. Götte, M., Echtermeyer, F. Syndecan-1 as a regulator of chemokine function. Scientific World J., 2003, 3, 1327-1331.
7. Griffith, J.W., Sokol, C.L., Luster, A.D. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu. Rev. Immunol., 2014, 32, 659-702.
8. Hyduk, S.J., Chan, J.R., Duffy, S.T., Chen, M., Peterson, M.D., Waddell, T.K., Digby, G.C., Szaszi, K., Kapus, A., Cybulsky, M.I, Phospholipase C, calcium, and calmodulin are critical for alpha4beta1 integrin affinity up-regulation and monocyte arrest triggered by chemoattractants. Blood, 2007, 109, 176-184.
9. Vielkind, S., Gallagher-Gambarelli, M., Gomez, M., Hinton, H.J., Cantrell, D.A. Integrin regulation by RhoA in thymocytes. J. Immunol., 2005, 175, 350-357.
10. Zarbock, A., Kempf, T., Wollert, K.C., Vestweber, D. Leukocyte integrin activation and deactivation: novel mechanisms of balancing inflammation. J. Mol. Med. (Berl)., 2012, 90, 353-359.
11. Lefort, C.T., Rossaint, J., Moser, M., Petrich, B.G., Zarbock, A., Monkley, S.J., Critchley, D.R., Ginsberg, M.H., Fässler, R., Ley, K. Distinct roles for talin-1 and kindlin-3 in LFA-1 extension and affinity regulation. Blood, 2012, 119, 4275-4282.
12. Smith, C.W., Rothlein, R., Hughes, B.J., Mariscalco, M.M., Rudloff, H.E., Schmalstieg, F.C., Anderson, D.C. Recognition of an endothelial determinant for CD18-dependent human neutrophil adherence and transendothelial migration. J. Clin. Invest., 1988, 82, 1746-1756.
13. Phillipson, M., Heit, B., Colarusso, P., Liu, L., Ballantyne, C.M., Kubes, P. Intraluminal crawling of neutrophils to emigration sites: a molecularly distinct process from adhesion in the recruitment cascade. J. Exp. Med., 2006, 203, 2569-2575.
14. Massena, S., Christoffersson, G., Hjertstrom, E., Zcharia, E., Vlodavsky, I., Ausmees, N., Rolny, C., Li, J.P., Phillipson, M. A chemotactic gradient sequestered on endothelial heparan sulfate induces directional intraluminal crawling of neutrophils. Blood, 2010, 116, 1924-1931.
15. Hepper, I., Schymeinsky, J., Weckbach, L.T., Jakob, S.M., Frommhold, D., Sixt, M., Laschinger, M., Sperandio, M., Walzog, B. The mammalian actin-binding protein 1 is critical for spreading and intraluminal crawling of neutrophils under flow conditions. J. Immunol., 2012, 188, 4590-4601.
16. Phillipson, M., Heit, B., Parsons, S.A., Petri, B., Mullaly, S.C., Colarusso, P., Gower, R.M., Neely, G., Simon, S.I., Kubes P. Vav1 is essential for mechanotactic crawling and migration of neutrophils out of the inflamed microvasculature. J. Immunol., 2009, 182, 6870-6878.
17. Wojciechowski, J.C., Sarelius, I.H. Preferential binding of leukocytes to endothelial junction region in venules in situ. Microcirculation, 2005, 12, 349-359.
18. Heit, B., Robbins, S.M., Downey, C.M., Guan, Z., Colarusso, P., Miller, B.J., Jirik, F.R., Kubes, P. PTEN functions to ‘prioritize’ chemotactic cues and prevent ‘distraction’ in migrating neutrophils. Nat. Immunol., 2008, 9, 716-718.
19. Ebnet, K., Suzuki, A., Ohno, S., Vestweber, D. Junctional adhesion molecules (JAMs): more molecules with dual functions? J. Cell Sci., 2004, 117, 19-29.
20. Bixel, G., Kloep, S., Butz, S., Petri, B., Engelhardt, B., Vestweber, D. Mouse CD99 participates in T-cell recruitment into inflamed skin. Blood, 2004, 104, 3205-3213.
21. Woodfin, A., Voisin, M.B., Beyrau, M., Colom, B., Caille, D., Diapouli, F.M., Nash, G.B., Chavakis, T., Albelda, S.M., Rainger, G.E., Meda, P., Imhof, B.A., Nourshargh, S. The junctional adhesion molecule JAM-C regulates polarized transendothelial migration of neutrophils in vivo. Nat. Immunol., 2011, 12, 761-769.
22. Barreiro, O. , Yanez-Mo, M., Serrador, J.M., Montoya, M.C., Vicente-Manzanares, M., Tejedor, R., Furthmayr, H., Sanchez-Madrid, F. Dynamic interaction of VCAM‑1 and ICAM‑1 with moesin and ezrin in a novel endothelial docking structure for adherent leukocytes. J. Cell Biol., 2002, 157, 1233-1245.
23. Carman, C.V., Springer, T.A. A transmigratory cup in leukocyte diapedesis both through individual vascular endothelial cells and between them. J. Cell Biol., 2004, 167, 377-388.
24. Parsons, S.A., Sharma, R., Roccamatisi, D.L., Zhang, H., Petri, B., Kubes, P., Colarusso, P., Patel, K.D. Endothelial paxillin and focal adhesion kinase (FAK) play a critical role in neutrophil transmigration. Eur. J. Immunol., 2012, 42, 436-446.
25. Simon Davis, D.A., Parish, C.R. Heparan Sulfate: A Ubiquitous Glycosaminoglycan with Multiple Roles in Immunity. Front. Immunol., 2013, 4, 470.
26. Bernfield, M., Götte, M., Park, P.W., Reizes, O., Fitzgerald, M.L., Lincecum, J., Zako, M. Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem., 1999, 68, 729-777.
27. Kreuger, J., Kjellén, L. Heparan sulfate biosynthesis: regulation and variability. J. Histochem. Cytochem., 2012, 60, 898-907.
28. Kreuger, J., Spillmann, D., Li, J.P., Lindahl, U. Interactions between heparan sulfate and proteins: the concept of specificity. J. Cell Biol., 2006, 174, 323-327.
29. Götte, M., Spillmann, D., Yip, G.W., Versteeg, E., Echtermeyer, F.G., van Kuppevelt, T.H., Kiesel, L. Changes in heparan sulfate are associated with delayed wound repair, altered cell migration, adhesion and contractility in the galactosyltransferase I (beta4GalT-7) deficient form of Ehlers-Danlos syndrome. Hum. Mol. Genet., 2008, 17, 996-1009.
30. Kramer, K.L., Yost, H.J. Heparan sulfate core proteins in cell-cell signalling. Annu. Rev. Genet., 2003, 37, 461-484.
31. Rapraeger, A.C. Synstatin: a selective inhibitor of the syndecan-1-coupled IGF1R-αvβ3 integrin complex in tumorigenesis and angiogenesis. FEBS J., 2013, 280, 2207-2215.
32. Sarrazin, S., Lamanna, W.C., Esko, J.D. Heparan sulfate proteoglycans. Cold Spring Harb. Perspect. Biol., 2011, 3, 1-33.
33. Häcker, U., Nybakken, K., Perrimon, N. Heparan sulfate proteoglycans: the sweet side of development. Nat. Rev. Mol. Cell. Biol., 2005, 6, 530-541.
34. Bishop, J.R., Schuksz, M., Esko, J.D. Heparan sulfate proteoglycans fine-tune mammalian physiology. Nature, 2007, 446, 1030-1037.
35. Lindahl, U., Kjellen, L. Pathophysiology of heparan sulfate:many diseases, few drugs. J. Intern. Med., 2013, 273, 555-571.
36. Yip, G.W., Smollich, M., Götte M. Therapeutic value of glycosaminoglycans in cancer. Mol. Cancer Ther., 2006, 5, 2139-2148.
37. Zhang, D., Wan, A., Chiu, A.P., Wang, Y., Wang, F., Neumaier, K., Lal, N., Bround, M.J., Johnson, J.D., Vlodavsky, I., Rodrigues, B. Hyperglycemia-induced secretion of endothelial heparanase stimulates a vascular endothelial growth factor autocrine network in cardiomyocytes that promotes recruitment of lipoprotein lipase. Arterioscler. Thromb. Vasc. Biol., 2013, 33, 2830-2838.
38. Nikitovic, D., Mytilinaiou, M., Berdiaki, A., Karamanos, N.K., Tzanakakis, G.N. Heparan sulfate proteoglycans and heparin regulate melanoma cell functions. Biochim. Biophys. Acta., 2014, 1840, 2471-2481.
39. Hassan, H., Greve, B., Pavao, M.S., Kiesel, L., Ibrahim, S.A., Götte, M. Syndecan-1 modulates β-integrin-dependent and interleukin-6-dependent functions in breast cancer cell adhesion, migration, and resistance to irradiation. FEBS J., 2013, 280, 2216-2217.
40. Ibrahim, S.A., Hassan, H., Vilardo, L., Kumar, S.K., Kumar, A.V., Kelsch, R., Schneider, C., Kiesel, L., Eich, H.T., Zucchi, I., Reinbold, R., Greve, B., Götte, M. Syndecan-1 (CD138) modulates tri ple-negative breast cancer stem cell properties via regulation of LRP-6 and IL-6-mediated STAT3 signalling. PLoS One, 2013, 8, e85737.
41. Shao, C., Shi, X., White, M., Huang, Y., Hartshorn, K., Zaia J. Comparative glycomics of leukocyte glycosaminoglycans. FEBS J., 2013, 280, 2447-2461.
42. Schlessinger, J., Plotnikov, A.N., Ibrahimi, O.A., Eliseenkova, A.V., Yeh, B.K., Yayon, A., Linhardt, R.J., Mohammadi, M. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol. Cell, 2000, 6, 743-750.
43. Goger, B., Halden, Y., Rek, A., Mösl, R., Pye, D., Gallagher, J., Kungl, A.J. Different affinities of glycosaminoglycan oligosaccharides for monomeric and dimeric interleukin-8: a model for chemokine regulation at inflammatory sites. Biochemistry, 2002, 41, 1640-1646.
44. Shaw, J.P., Johnson, Z., Borlat, F., Zwahlen, C., Kungl, A., Roulin, K., Harrenga, A., Wells, T.N., Proudfoot, A.E. The X-ray structure of RANTES: heparin-derived disaccharides allows the rational design of chemokine inhibitors. Structure, 2004, 12, 2081-2093.
45. Middleton, J., Patterson, A.M., Gardner, L., Schmutz, C., Ashton, B.A. Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood, 2002, 100, 3853-3860.
46. Koenig, A., Norgard-Sumnicht, K., Linhardt, R., Varki, A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J. Clin. Invest., 1998, 101, 877-889.
47. Wang, L., Fuster, M., Sriramarao, P., Esko, J.D. Endothelial heparan sulfate deficiency impairs L-selectin-and chemokinemediated neutrophil trafficking during inflammatory responses. Nat. Immunol., 2005, 6, 902-910.
48. Lortat-Jacob, H., Grosdidier, A., Imberty, A. Structural diversity of heparan sulfate binding domains in chemokines. Proc. Natl. Acad. Sci. U.S.A., 2002, 99, 1229-1234.
49. Lortat-Jacob, H. The molecular basis and functional implications of chemokine interactions with heparan sulfate. Curr. Opin. Struct. Biol., 2009, 19, 543-548.
50. Wrenshall, L.E., Cerra, F.B., Singh, R.K., Platt, J.L. Heparan sulfate initiates signals in murine macrophages leading to divergent biologic outcomes. J. Immunol., 1995, 54, 871-880.
51. Douglas, M.S., Rix, D.A., Dark, J.H., Talbot, D., Kirby, J.A. Examination of the mechanism by which heparin antagonizes activation of a model endothelium by interferon gamma (IFN-gamma). Clin. Exp. Immunol., 1997, 107, 578-584.
52. Clasper, S., Vekemans, S., Fiore, M., Plebanski, M., Wordsworth, P., David, G., Jackson, D.G. Inducible expression of the cell surface heparan sulfate proteoglycan syndecan-2 (fibroglycan) on human activated macrophages can regulate fibroblast growth factor action. J. Biol. Chem., 1999, 274, 24113-24123.
53. Elenius, K., Vainio, S., Laato, M., Salmivirta, M., Thesleff, I., Jalkanen, M. Induced expression of syndecan in healing wounds. J. Cell Biol., 1991, 114, 585-595.
54. Götte, M., Joussen, A.M., Klein, C., Andre, P., Wagner, D.D., Hinkes, M.T., Kirchhof, B., Adamis, A.P., Bernfield, M. Role of syndecan-1 in leukocyte-endothelial interactions in the ocular vasculature. Invest. Ophthalmol. Vis. Sci., 2002, 43, 1135-1141.
55. Zhang, Y., Pasparakis, M., Kollias, G., Simons, M. Myocytedependent regulation of endothelial cell syndecan-4 expression. Role of TNF-a. J. Biol. Chem., 1999, 274, 14786-14790.
56. Johnson, G.B., Brunn, G.J., Kodaira, Y., Platt, J.L. Receptormediated monitoring of Tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J. Immunol., 2002, 168, 5233-5239.
57. Smith, M.F. Jr., Novotny, J., Carl, V.S., Comeau, L.D. Helicobacter pylori and toll-like receptor agonists induce syndecan-4 expression in an NF-kappaB-dependent manner. Glycobiology, 2006, 16, 221-229.
58. Brunn, G.J., Bungum, M.K., Johnson, G.B., Platt, J.L. Conditional signalling by Toll-like receptor 4. FASEB J., 2005, 19, 872-874.
59. Schmidt, E.P., Yang, Y., Janssen, W.J., Gandjeva, A., Perez, M.J., Barthel, L., Zemans, R.L., Bowman, J.C., Koyanagi, D.E., Yunt, Z.X., Smith, L.P., Cheng, S.S., Overdier, K.H., Thompson, K.R., Geraci, M.W., Douglas, I.S., Pearse, D.B., Tuder, R.M. The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during bexperimental sepsis. Nat. Med., 2012, 18, 1217-1223.
60. Kitamura, N., Yamaguchi, M., Shimabukuro, K., Miyasaka, M., Nakano, H., Kumada, K. Heparin-like glycosaminoglycans inhibit leukocyte adhesion to endotoxin-activated human vascular endothelial cells under nonstatic conditions. Eur. Surg. Res., 1996, 28, 428-435.
61. Giuffre, L., Cordey, A.S., Monai, N., Tardy, Y., Schapira, M., Spertini, O. Monocyte adhesion to activated aortic endothelium: role of L-selectin and heparan sulfate proteoglycans. J. Cell Biol., 1997, 136, 945-956.
62. Xie, X., Rivier, A.-S., Zakrzewicz, A., Bernimoulin, M., Zeng, X.-L., Wessel, H. P., Schapira, M., Spertini, O. Inhibition of selectinmediated cell adhesion and prevention of acute inflammation by nonanticoagulant sulfated saccharides. J. Biol. Chem., 2000, 275, 34818-34825.
63. Wan, M.X., Zhang, X.W., Torkvist, L., Thorlacius, H. Low molecular weight heparin inhibits tumor necrosis factor alpha-induced leukocyte rolling. Inflamm. Res., 2001, 50, 581-584.
64. Axelsson, J., Xu, D., Kang, B.N., Nussbacher, J.K., Handel, T.M., Ley, K., Sriramarao, P., Esko, J.D. Inactivation of heparan sulfate 2-O-sulfotransferase accentuates neutrophil infiltration during acute inflammation in mice. Blood, 2012, 120, 1742-1751.
65. Hoogewerf, A.J., Kuschert, G.S., Proudfoot, A.E., Borlat, F., Clark-Lewis, I., Power, C.A., Wells, T.N. Glycosaminoglycans mediate cell surface oligomerization of chemokines. Biochemistry, 1997, 36, 13570-13578.
66. Patel, D.D., Koopmann, W., Imai, T., Whichard, L.P., Yoshie, O., Krangel, M.S. Chemokines have diverse abilities to form solid phase gradients. Clin. Immunol., 2001, 99, 43-52.
67. Webb, L.M., Ehrengruber, M.U., Clark-Lewis, I. Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin 8. Proc. Natl. Acad. Sci. U.S.A., 1993, 90, 7158-7162.
68. Schumann, K., Lämmermann, T. Bruckner, M., Legler, D.F., Polleux, J., Spatz, J.P., Schuler, G., Förster, R., Lutz, M.B., Sorokin, L., Sixt, M. Immobilized chemokine fields and soluble chemokine gradients cooperatively shape migration patterns of dendritic cells. Immunity, 2010, 32, 703-713.
69. Ihrcke, N.S., Wrenshall, L.E., Lindman, B.J., Platt, J.L. Role of heparan sulfate in immune system-blood vessel interactions. Immunol. Today, 1993, 14, 500-505.
70. Wang, Z., Götte, M., Bernfield, M., Reizes, O. Constitutive and accelerated shedding of murine syndecan-1 is mediated by cleavage of its core protein at a specific juxtamembrane site. Biochemistry, 2005, 44, 12355-12361.
71. Hayashida, K., Parks, W.C., Park, P.W. Syndecan-1 shedding facilitates the resolution of neutrophilic inflammation by removing sequestered CXC chemokines. Blood, 2009, 114, 3033-3043.
72. Marshall, L.J., Ramdin, L.S., Brooks, T., Charlton, P., Shute, J.K. Plasminogen activator inhibitor-1 supports IL-8-mediated neutrophil transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8/heparan sulfate/syndecan-1 complexes. J. Immunol., 2003, 171, 2057-2065.
73. Tanaka, Y., Kimata, K., Wake, A., Mine, S., Morimoto, I., Yamakawa, N., Habuchi, H., Ashikari, S., Yamamoto, H., Sakurai, K; Yoshida K, Suzuki S; Eto S. Heparan sulfate proteoglycan on leukemic cells is primarily involved in integrin triggering and its mediated adhesion to endothelial cells. J. Exp. Med., 1996, 184, 1987-1997.
74. Savery, M.D., Jiang, J.X., Park, P.W., Damiano, E.R. The endothelial glycocalyx in syndecan-1 deficient mice. Microvasc. Res., 2013, 87, 83-91.
75. Floer, M., Götte, M., Wild, M.K., Heidemann, J., Gassar, E.S., Domschke, W., Kiesel, L., Luegering, A., Kucharzik, T. Enoxaparin improves the course of dextran sodium sulfate-induced colitis in syndecan-1-deficient mice. Am. J. Pathol., 2010, 176, 146-157.
76. Rops, A.L., Götte, M., Baselmans, M.H., van den Hoven, M.J., Steenbergen, E.J., Lensen, J.F., Wijnhoven, T.J., Cevikbas, F., van den Heuvel, L.P., van Kuppevelt, T.H., Berden, J.H., van der Vlag, J. Syndecan-1 deficiency aggravates anti-glomerular basement membrane nephritis. Kidney Int., 2007, 72, 1204-1215.
77. Vanhoutte, D., Schellings, M.W., Götte, M., Swinnen, M., Herias, V., Wild, M.K., Vestweber, D., Chorianopoulos, E., Cortés, V., Rigotti, A., Stepp, M.A., Van de Werf, F., Carmeliet, P., Pinto, Y.M., Heymans, S. Increased expression of syndecan-1 protects against cardiac dilatation and dysfunction after myocardial infarction. Circulation, 2007, 115, 475-482.
78. Kharabi Masouleh, B., Ten Dam, G.B., Wild, M.K., Seelige, R., van der Vlag, J., Rops, A.L., Echtermeyer, F.G., Vestweber, D., van Kuppevelt, T.H., Kiesel, L., Götte, M. Role of the heparan sulfate proteoglycan syndecan-1 (CD138) in delayed-type hypersensitivity. J. Immunol., 2009, 182, 4985-4993.
79. Zhang, X., Wu, C., Song, J., Götte, M., Sorokin, L. Syndecan-1, a cell surface proteoglycan, negatively regulates initial leukocyte recruitment to the brain across the choroid plexus in murine experimental autoimmune encephalomyelitis. J. Immunol., 2013, 191, 4551-4561.
80. Götte, M., Yip, G.W. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res., 2006, 66, 10233-10237.
81. Kato, M., Wang, H., Kainulainen, V., Fitzgerald, M.L., Ledbetter, S., Ornitz, D.M., Bernfield, M. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat. Med., 1998, 4, 691-697.
82. Edovitsky, E., Lerner, I., Zcharia, E., Peretz, T., Vlodavsky, I., Elkin, M. Role of endothelial heparanase in delayed-type hypersensitivity. Blood, 2006, 107, 3609-3616.
83. Lerner I; Hermano E; Zcharia E; Rodkin D; Bulvik R; Doviner V; Rubinstein AM; Ishai-Michaeli R; Atzmon R; Sherman Y; Meirovitz A; Peretz T; Vlodavsky I; Elkin M. Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J. Clin. Invest., 2011; 121, 1709-1721.
84. Meirovitz, A., Goldberg, R., Binder, A., Rubinstein, A.M., Hermano, E., Elkin, M. Heparanase in inflammation and inflammationassociated cancer. FEBS J., 2013, 280, 2307-2319.
85. Ramani, V.C., Purushothaman, A., Stewart, M.D., Thompson, C.A., Vlodavsky, I., Au, J.L., Sanderson, R.D. The heparanasel syndecan-1 axis in cancer: mechanisms and therapies. FEBS J., 2013, 280, 2294-2306.
86. Gomes, A.M., Stelling, M.P., Pavão, M.S. Heparan sulfate and heparanase as modulators of breast cancer progression. Biomed. Res. Int., 2013, 2013, 852-093.
87. Götte, M., Bernfield, M., Joussen, A.M. Increased leukocyteendothelial interactions in syndecan-1-deficient mice involve heparan sulfate-dependent and-independent steps. Curr. Eye Res., 2005, 30, 417-422.
88. Ballut, L., Sapay, N., Chautard, E., Imberty, A., Ricard-Blum, S. Mapping of heparin/heparan sulfate binding sites on avb3 integrin by molecular docking. J. Mol. Recognit., 2013, 26, 76-85.
89. Ibrahim, S.A., Yip, G.W., Stock, C., Pan, J.W., Neubauer, C., Poeter, M., Pupjalis, D., Koo, C.Y., Kelsch, R., Schüle, R., Rescher, U., Kiesel, L., Götte, M. Targeting of syndecan-1 by microRNA miR-10b promotes breast cancer cell motility and invasiveness via a Rho-GTPase-and E-cadherin-dependent mechanism. Int. J. Cancer., 2012, 131, E884-96.
90. Rovira-Clavé, X., Angulo-Ibáñez, M., Reina, M., Espel, E. The PDZ-binding domain of syndecan-2 inhibits LFA-1 high-affinity conformation. Cell. Signal., 2014, 26, 1489-1499.
91. Seidler, D.G., Mohamed, N.A., Bocian, C., Stadtmann, A., Hermann, S., Schäfers, K., Schäfers, M., Iozzo, R.V., Zarbock, A., Götte, M. The role for decorin in delayed-type hypersensitivity. J. Immunol., 2011, 187, 6108-6119.
92. Bocian, C., Urbanowitz, A.K., Owens, R.T., Iozzo, R.V., Götte, M., Seidler, D.G. Decorin potentiates interferon-γ activity in a model of allergic inflammation. J. Biol. Chem., 2013, 288, 12699-12711.
93. Li, L., Wang, B., Gao, T., Zhang, X., Hao, J.X., Vlodavsky, I., Wiesenfeld-Hallin, Z., Xu, X.J., Li, J.P. Heparanase overexpression reduces carrageenan-induced mechanical and cold hypersensitivity in mice. Neurosci. Lett., 2012, 511, 4-7.
94. Zhang, X., Wang, B., O'Callaghan, P., Hjertström, E., Jia, J., Gong, F., Zcharia, E., Nilsson, L.N., Lannfelt, L., Vlodavsky, I., Lindahl, U., Li, J.P. Heparanase overexpression impairs inflammatory response and macrophage-mediated clearance of amyloid-β in murine brain. Acta Neuropathol., 2012, 124, 465-478.
95. Zen, K., Liu, D.Q., Li, L.M., Chen, C.X., Guo, Y.L., Ha, B., Chen, X., Zhang, C.Y., Liu, Y. The heparan sulfate proteoglycan form of epithelial CD44v3 serves as a CD11b/CD18 counter-receptor during polymorphonuclear leukocyte transepithelial migration. J. Biol. Chem., 2009, 284, 3768-3776.
96. Ali, S., Palmer, A. C., Fritchley, S. J., Maley, Y., Kirby, J. A. Multimerization of monocyte chemoattractant protein-1 is not required for glycosaminoglycan-dependent transendothelial chemotaxis. Biochem. J., 2001, 358, 737-745.
97. Dyer, D.P., Thomson, J.M., Hermant, A., Jowitt, T.A., Handel, T.M., Proudfoot, A.E., Day, A.J., Milner, C.M. TSG-6 inhibits neutrophil migration via direct interaction with the chemokine CXCL8. J. Immunol., 2014, 192, 2177-2185.
98. Xu, J., Park, P.W., Kheradmand, F., Corry, D.B. Endogenous attenuation of allergic lung inflammation by syndecan-1. J. Immunol., 2005, 174, 5758-5765.
99. Bao, X., Moseman, E.A., Saito, H., Petryniak, B., Thiriot, A., Hatakeyama, S., Ito, Y., Kawashima, H., Yamaguchi, Y., Lowe, J.B., von Andrian, U.H., Fukuda, M. Endothelial heparan sulfate controls chemokine presentation in recruitment of lymphocytes and dendritic cells to lymph nodes. Immunity, 2010, 33, 817-829.
100. Stoler-Barak, L., Barzilai, S., Zauberman, A., Alon, R. Transendothelial migration of effector T cells across inflamed endothelial barriers does not require heparan sulfate proteoglycans. Int. Immunol., 2014, 26, 315-324.
101. Barash, U., Cohen-Kaplan, V., Dowek, I., Sanderson, R.D., Ilan, N., Vlodavsky, I. Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J., 2010, 277, 3890-3903.
102. Garsen, M., Rops, A.L., Rabelink, T.J., Berden, J.H., van der Vlag, J. The role of heparanase and the endothelial glycocalyx in the development of proteinuria. Nephrol. Dial. Transplant., 2014, 29, 49-55.
103. Korpos, E., Wu, C., Sorokin, L. Multiple roles of the extracellular matrix in inflammation. Curr. Pharm. Des., 2009, 15, 1349-1357.
104. Kawashima, H., Watanabe, N., Hirose, M., Sun, X., Atarashi, K., Kimura, T., Shikata, K., Matsuda, M., Ogawa, D., Heljasvaara, R., Rehn, M., Pihlajaniemi, T., Miyasaka M. Collagen XVIII,a basement membrane heparan sulfate proteoglycan, interacts with Lselectin and monocyte chemoattractant protein-1. J. Biol. Chem., 2003, 278, 13069-13076.
105. Celie, J.W., Keuning, E.D., Beelen, R.H., Drager, A.M., Zweegman, S., Kessler, F.L., Soininen, R.., van den Born, J. Identification of L-selectin binding heparan sulfates attached to collagen type XVIII. J. Biol. Chem., 2005, 280, 26965-26973.
106. Vlodavsky, I., Eldor, A., Haimovitz-Friedman, A., Matzner, Y., Ishai-Michaeli, R., Lider, O., Naparstek, Y., Cohen, I.R., Fuks, Z. Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis, 1992, 12, 112-127.
107. Sasaki, N., Higashi, N., Taka, T., Nakajima, M., Irimura, T. Cell surface localization of heparanase on macrophages regulates degradation of extracellular matrix heparan sulfate. J. Immunol., 2004, 172, 3830-3835.
108. Fridman, R., Lider, O., Naparstek, Y., Fuks, Z., Vlodavsky, I., Cohen, I.R. Soluble antigen induces T lymphocytes to secrete an endoglycosidase that degrades the heparan sulfate moiety of subendothelial extracellular matrix. J. Cell. Physiol., 1987, 130, 85-92.
109. Benhamron, S., Nechushtan, H., Verbovetski, I., Krispin, A., Abboud-Jarrous, G., Zcharia, E., Edovitsky, E., Nahari, E., Peretz, T., Vlodavsky, I., Mevorach, D. Translocation of active heparanase to cell surface regulates degradation of extracellular matrix heparan sulfate upon transmigration of mature monocyte-derived dendritic cells. J. Immunol., 2006, 176, 6417-6424.
110. Benhamron, S., Reiner, I., Zcharia, E., Atallah, M., Grau, A., Vlodavsky, I., Mevorach, D. Dissociation between mature phenotype and impaired transmigration in dendritic cells from heparanasedeficient mice. PLoS One, 2012, 7, e35602.
111. Zcharia E; Jia J; Zhang X; Baraz L; Lindahl U; Peretz T; Vlodavsky I; Li JP. Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases. PLoS One, 2009, 4, e5181
112. Purushothaman, A., Hurst, D.R., Pisano, C., Mizumoto, S., Sugahara, K., Sanderson, R.D. Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype. J. Biol. Chem., 2011, 286, 30377-30383.
113. Lindahl, U. Heparan sulfate-protein interactions--a concept for drug design? Thromb. Haemost., 2007, 98, 109-115.
114. Parish, C.R. The role of heparan sulfate in inflammation. Nat. Rev. Immunol., 2006, 6, 633-643.
115. Wang, L., Brown, J.R., Varki, A., Esko, J.D. Heparin's antiinflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L-and P-selectins. J. Clin. Invest., 2002, 110, 127-136.
116. Capila, I., Linhardt, R.J. Heparin-protein interactions. Angew. Chem. Int. Ed. Engl., 2002, 41, 391-412.
117. Lever, R., Page, C.P. Novel drug development opportunities for heparin. Nature Rev. Drug Discov., 2002, 1, 140-148.
118. Spillmann, D., Witt, D., Lindahl, U. Defining the interleukin-8-binding domain of heparan sulfate. J. Biol. Chem., 1998, 273, 15487-15493.
119. Khachigian, L.M., Parish, C.R. Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with clinical potential in multiple vascular pathologies. Cardiov. Drug Rev., 2004, 22, 1-6.
120. Naggi, A., Casu, B., Perez, M., Torri, G., Cassinelli, G., Penco, S., Pisano, C., Giannini, G., Ishai-Michaeli, R., Vlodavsky, I. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation; graded N-acetylation; and glycol splitting. J. Biol. Chem., 2005, 280, 12103-12113.
121. Vlodavsky, I., Ilan, N., Naggi, A., Casu, B. Heparanase: structure; biological functions; and inhibition by heparin-derived mimetics of heparan sulfate. Curr. Pharm. Des., 2007, 13, 2057-2073.
122. Harris, N., Kogan, F.Y., Il'kova, G., Juhas, S., Lahmy, O., Gregor, Y.I., Koppel, J., Zhuk, R., Gregor, P. Small molecule inhibitors of protein interaction with glycosaminoglycans (SMIGs); a novel class of bioactive agents with anti-inflammatory properties. Biochim. Biophys. Acta., 2014, 1840, 245-254.